126541-81-9

Usage

Uses

Used in Organic Synthesis:
Methyl 3-nitro-4-trifluoromethylbenzoate is used as a building block in organic synthesis for the creation of various organic compounds. Its unique structure and reactivity make it a valuable component in the synthesis of complex organic molecules.
Used in Pharmaceutical Research:
In the pharmaceutical industry, Methyl 3-nitro-4-trifluoromethylbenzoate is used as a key intermediate in the development of new drugs. Its versatile chemical properties allow for the exploration of its potential applications in medicinal chemistry, including the synthesis of novel therapeutic agents.

InChI:InChI=1/C9H6F3NO4/c1-17-8(14)5-2-3-6(9(10,11)12)7(4-5)13(15)16/h2-4H,1H3

Upstream product

• 116965-16-3 3-nitro-4-(trifluoromethyl)benzoic acid 
• 74-88-4 methyl iodide 
• 680-15-9 2,2-difluoro-2-(fluorosulfonyl)acetate 
• 2363-16-8 methyl 4-bromo-3-nitrobenzoate 
• 6319-40-0 4-bromo-3-nitrobenzoic acid 
• 455-24-3 4-trifluoromethylbenzoic acid 
• 186581-53-3 diazomethane 

Downstream Products

• 126541-82-0 3-Amino-4-(trifluormethyl)benzoesaeure-methylester 
• 581813-17-4 3-bromo-4-(trifluoromethyl)benzoic acid 

Relevant academic research and scientific papers

INACTIVATORS OF TOXOPLASMA GONDII ORNITHINE AMINOTRANSFERASE FOR TREATING TOXOPLASMOSIS AND MALARIA

Disclosed are methods, compounds, and compositions for treating infection by an Apicomplexan parasite that include administering a compound that selectively inactivates ornithine aminotransferase of the Apicomplexan parasite. Specifically, the methods, co

TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF

The present invention is directed to bicyclic heteroaryl benzamide compounds of formulas (I) which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.

TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF

The present invention is directed to substituted five membered heteroaryl benzamide compounds compounds of formula (I), which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.

TRKA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF

The present invention is directed to six membered heteroaryl benzamide compounds of formula (I), which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.

TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF

The present invention is directed to a bicyclic heteroaryl benzamide compounds of formula(I) which are tropomyosin-related kinase(Trk)family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF)receptor TrkA.

Demethyl(trifluoromethyl)actinomycins

The synthesis of new 4-(trifluoromethyl)benzoic acid derivatives 2-10 and their coupling with amino acids and peptides 12, 13, 15 is described.They serve as precursors for the synthesis of the hitherto unknown demethyl(trifluoromethyl)actinocin dimethyl esters 11, demethyl-trifluoromethyl-actinocinyl peptides 14, 16, 18 and the demethyl-trifluoromethyl-actinomycins 17.Although spacially comparable with the methyl residues, the 4- and 6-trifluoromethyl groups have unexpected strong influences on the antibiotic and cytostatic properties of the actinomycins.The CH3/CF3 exchange makes it possible to bring NMR-analytically useful hetero nuclei into the centre of the actinomycin/DNA complex (Figure 1).